# DLL3 CAR-T Therapy Targeting Brain Tumors

> **NCT07180927** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma of Cerebellum

## Interventions

- **BIOLOGICAL:** 4SCAR DLL3 T cells

## Key facts

- **NCT ID:** NCT07180927
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180927, "DLL3 CAR-T Therapy Targeting Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07180927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*